Publication:
Bronchopulmonary penetration of isavuconazole in lung transplant recipients

dc.contributor.authorCaballero-Bermejo, Antonio F
dc.contributor.authorDarnaude-Ximénez, Ignacio
dc.contributor.authorAguilar-Pérez, Myriam
dc.contributor.authorGomez-Lopez, Alicia
dc.contributor.authorSancho-López, Aránzazu
dc.contributor.authorLópez García-Gallo, Cristina
dc.contributor.authorDíaz Nuevo, Gema
dc.contributor.authorDiago-Sempere, Elena
dc.contributor.authorRuiz-Antorán, Belén
dc.contributor.authorAvendaño-Solá, Cristina
dc.contributor.authorUssetti-Gil, Piedad
dc.contributor.authorPBISA01-Study Group
dc.contributor.funderPfizer
dc.date.accessioned2023-11-14T11:19:18Z
dc.date.available2023-11-14T11:19:18Z
dc.date.issued2023-10-18
dc.description.abstractIsavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was partially supported and funded by Pfizer (grant 54685521). Pfizer had no role in the study’s design; the collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publicationes_ES
dc.format.number10es_ES
dc.format.pagee0061323es_ES
dc.format.volume67es_ES
dc.identifier.citationAntimicrob Agents Chemother. 2023 Oct 18;67(10):e0061323.es_ES
dc.identifier.doi10.1128/aac.00613-23es_ES
dc.identifier.e-issn1098-6596es_ES
dc.identifier.journalAntimicrobial agents and chemotherapyes_ES
dc.identifier.pubmedID37787528es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16667
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM)
dc.relation.publisherversionhttps://doi.org/10.1128/aac.00613-23es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectIsavuconazolees_ES
dc.subjectInvasive fungal infectiones_ES
dc.subjectBronchoalveolar lavagees_ES
dc.subjectTissue penetrationes_ES
dc.subjectLung transplantes_ES
dc.subject.meshTransplant Recipientses_ES
dc.subject.meshLunges_ES
dc.subject.meshHumanses_ES
dc.subject.meshBronchoalveolar Lavage Fluides_ES
dc.subject.meshTriazoleses_ES
dc.titleBronchopulmonary penetration of isavuconazole in lung transplant recipientses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationa93f0030-19b4-4bed-b7d3-b03b53876436
relation.isAuthorOfPublication.latestForDiscoverya93f0030-19b4-4bed-b7d3-b03b53876436
relation.isFunderOfPublicationef9bda09-43e0-4391-b045-f15b8571dc48
relation.isFunderOfPublication.latestForDiscoveryef9bda09-43e0-4391-b045-f15b8571dc48
relation.isPublisherOfPublication30cd8aef-e018-40d1-b05e-19af778995bd
relation.isPublisherOfPublication.latestForDiscovery30cd8aef-e018-40d1-b05e-19af778995bd

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
BronchopulmonaryPenetrationIsavuconazoleLung_2023.pdf
Size:
2.71 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Supplementary1_BronchopulmonaryPenetrationIsavuconazoleLung_2023.pdf
Size:
757.47 KB
Format:
Adobe Portable Document Format
Description:
Supplementary material 1
Loading...
Thumbnail Image
Name:
Supplementary2_BronchopulmonaryPenetrationIsavuconazoleLung_2023.pdf
Size:
413.09 KB
Format:
Adobe Portable Document Format
Description:
Supplementary material 2